Balyasny Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Balyasny Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,100	Closed	-$541K	–	2921
2025 Q4	$541K	Buy	+9,100	New	+$495K	﹤0.01%	2488
2024 Q4	–	Sell	-50,000	Closed	-$3.51M	–	2753
2024 Q3	$3.51M	Buy	50,000 +29,700	+146%	+$2.48M	0.01%	1425
2024 Q2	$1.67M	Buy	+20,300	New	+$1.69M	﹤0.01%	1591
2024 Q1	–	Sell	-100,000	Closed	-$9.64M	–	2630
2023 Q4	$9.64M	Buy	+100,000	New	+$8.85M	0.02%	881
2021 Q1	–	Sell	-53,000	Closed	-$4.65M	–	1768
2020 Q4	$4.65M	Buy	+53,000	New	+$4.2M	0.03%	673
2020 Q3	–	Sell	-100,000	Closed	-$12.3M	–	1302
2020 Q2	$12.3M	Buy	+100,000	New	+$9.94M	0.11%	291
2019 Q4	–	Sell	-50,000	Closed	-$3.37M	–	1169
2019 Q3	$3.37M	Hold	50,000	–	–	0.02%	624
2019 Q2	$4.4M	Buy	+50,000	New	+$4.28M	0.03%	646
2018 Q3	–	Sell	-368,700	Closed	-$34.7M	–	1680
2018 Q2	$34.7M	Buy	+368,700	New	+$32.3M	0.16%	175

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's BMRN Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 1,362,752 shares worth $77M. The stake represents 0.1% of the portfolio and ranks #227 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in BMRN as recently as Q3 2025.

Balyasny Asset Management first reported a position in BMRN in Q2 2014 and has held it in 41 quarters since. The position peaked at $156M in Q4 2017. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Balyasny Asset Management held 1,362,752 shares of BioMarin Pharmaceuticals worth $77M as of Q1 2026.
BioMarin Pharmaceuticals was a new Balyasny Asset Management position in Q1 2026.
BioMarin Pharmaceuticals made up 0.1% of Balyasny Asset Management's portfolio in Q1 2026, its #227 holding.
Balyasny Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 41 quarters since.
Balyasny Asset Management's BioMarin Pharmaceuticals position peaked at $156M in Q4 2017.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.